MaxCyte’s FY20 trading statement shows 21% revenue growth to $26.2m (H220 up 15% to $15.3m), despite COVID impacts. Potential pre-commercialisation milestones have increased from >$800m to >$950m, with 140+ partnered programmes and 100+ covered by clinical licences. This strong performance accompanies recognition of the role of MaxCyte’s technology platform and know-how in enabling next-generation cell and gene therapies. Momentum is expected to flow into 2021, with continued revenue growth and new deals. Increasing visibility of the progress of partner clinical assets improves understanding of how these future income streams will drive major value. New funds raised should help augment MaxCyte’s leading position and have attracted further specialist investors ahead of the NASDAQ IPO. Our £1bn ($1.3bn) valuation (1217p/share) better captures potential value from the partner pipeline.
08 Feb 2021
Better visibility brings future into focus
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Better visibility brings future into focus
MaxCyte, Inc. (MXCT:LON) | 345 0 0.0% | Mkt Cap: 359.2m
- Published:
08 Feb 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
11
MaxCyte’s FY20 trading statement shows 21% revenue growth to $26.2m (H220 up 15% to $15.3m), despite COVID impacts. Potential pre-commercialisation milestones have increased from >$800m to >$950m, with 140+ partnered programmes and 100+ covered by clinical licences. This strong performance accompanies recognition of the role of MaxCyte’s technology platform and know-how in enabling next-generation cell and gene therapies. Momentum is expected to flow into 2021, with continued revenue growth and new deals. Increasing visibility of the progress of partner clinical assets improves understanding of how these future income streams will drive major value. New funds raised should help augment MaxCyte’s leading position and have attracted further specialist investors ahead of the NASDAQ IPO. Our £1bn ($1.3bn) valuation (1217p/share) better captures potential value from the partner pipeline.